Published October 7, 2019
| Version v1
Dataset
Open
Purification of Q23 and Q54 HTT and HTT-HAP40 from Sf9 2019/10/07
- 1. Structural Genomics Consortium, University of Toronto
Description
Project: Biophysical investigation of purified HTT protein samples
Experiment: Purification of Q23 and Q54 HTT and HTT-HAP40 from Sf9
Date completed: 2019/10/07
Rationale: Purification of HTT and HTT-HAP40 Q23 and Q54 for different biophysical and functional analyses
Notes
Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files
Purification of HTT and HTT-HAP40 Q23 and Q54 for different biophysical and functional analyses 20191007.pdf
Files
(930.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:4907cfe2b82647f8223e4473b775dafb
|
600.0 kB | Download |
|
md5:0cc10a664692cbffb6a11b4ccbe63e84
|
330.7 kB | Preview Download |